Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

476
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

398
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
398
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

758
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
758
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

321
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
321
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Maximal Oxygen Consumption in Cardiac Rehabilitation Patients: The Role of Sex.

Journal of clinical medicine·2026
Same author

Correction to: Diagnosis and treatment of iron deficiency in chronic heart failure.

Wiener klinische Wochenschrift·2025
Same author

Diagnosis and treatment of iron deficiency in chronic heart failure : Position statement of the heart failure working group of the Austrian Society of Cardiology.

Wiener klinische Wochenschrift·2025
Same author

Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms.

Wiener klinische Wochenschrift·2021
Same author

Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world.

Wiener klinische Wochenschrift·2020
Same author

Complete Revascularization with Multivessel PCI for Myocardial Infarction.

The New England journal of medicine·2020

Related Experiment Video

Updated: Feb 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

[Therapeutic options in hyperlipidemia].

Robert Berent1, Theresa Berent2, Helmut Sinzinger2

  • 1HerzReha Bad Ischl, Gartenstraße 9, 4820, Bad Ischl, Österreich. robert.berent@herzreha.at.

Wiener Medizinische Wochenschrift (1946)
|September 16, 2017
PubMed
Summary
This summary is machine-generated.

Effective management of lipid disorders is crucial for preventing atherosclerosis. Residential cardiac rehabilitation offers a unique opportunity to optimize lipid-lowering therapies, including statins and advanced treatments like PCSK9 inhibitors.

Keywords:
HypercholesterolemiaHypertriglyceridemiaLipoprotein(a)PCSK9Statins

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K

Related Experiment Videos

Last Updated: Feb 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Preventive Medicine

Background:

  • Dyslipidemia is a primary target for atherosclerosis prevention and progression management.
  • Lifestyle modifications are the initial approach to improving lipid profiles.
  • Statins are central to reducing low-density lipoprotein (LDL) cholesterol.

Purpose of the Study:

  • To highlight the importance of comprehensive lipid management in atherosclerosis.
  • To emphasize the role of residential cardiac rehabilitation in optimizing lipid-lowering strategies.
  • To discuss the consideration of advanced therapies based on disease severity.

Main Methods:

  • Focus on lifestyle modifications as a first step.
  • Utilize statin therapy for LDL cholesterol reduction.
  • Assess the need for treating other lipids (triglycerides, lipoprotein(a)) based on atherosclerotic disease extent.
  • Leverage a 4-week face-to-face contact in residential cardiac rehabilitation for adherence and medication adaptation.
  • Consider PCSK9 inhibitors and lipoprotein apheresis for specific indications.

Main Results:

  • Lifestyle changes improve plasma lipid profiles.
  • Statins effectively reduce LDL cholesterol.
  • Treatment of other lipids and advanced therapies are tailored to individual atherosclerotic disease progression.
  • Residential cardiac rehabilitation facilitates personalized and adaptive lipid management.

Conclusions:

  • Comprehensive management of dyslipidemia is essential for cardiovascular health.
  • Personalized treatment strategies, including advanced therapies, are vital for managing atherosclerosis.
  • Residential cardiac rehabilitation provides an optimal setting for intensive lipid management and patient support.